Masaaki Nishi

Masaaki Nishi

Auto-generated profile, based on publicly available information

Masaaki Nishi

Department of Surgery, Tokushima University, Tokushima, Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2018 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
TETumenjin Enkhbat
Tumenjin Enkhbat
MNMasaaki Nishi
Masaaki Nishi
CTChie Takasu
Chie Takasu
KYKozo Yoshikawa
Kozo Yoshikawa
HJHigashijima Jun
Higashijima Jun
MSMitsuo Shimada
Mitsuo Shimada
Background/Aim: Programmed cell death protein 1 (PD-1)/ programmed cell death ligand 1(PD-L1) axis is associated with immune tolerance via inhibition of T cell activation. The aim of this study was to clarify the significance of PD-1 and PD-L1 expressions and analyze the relationships between PD-1, PD-L1, transforming growth factor-β (TGF-β) and Forkhead box P3 (Foxp3) expressions in colorectal cancer (CRC). Patients and Methods: A total of 116 patients who underwent curative colectomy for stage II/III CRC were included in the study. PD-1, PD-L1, TGF-β, and Foxp3 expressions were examined by immunohistochemistry and related to prognostic factors by Kaplan–Meier. Results: PD-1 expression was correlated with PD-L1, TGF-β, and Foxp3 expressions. Overall survival rates were significantly poorer in the PD-1 and PD-L1-positive groups. Multivariate analysis showed that PD-L1-positive is an independent risk factor. Disease-free survival (DFS) was tended in the PD-L1-positive group. The group with double-positive expression had significantly poorer prognosis. Conclusion: PD-1 and PD-L1 expressions were associated with a poor prognosis and correlated with TGF-β and Foxp3 expressions in patients with CRC.

29 March 2021 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
SYShinichiro Yamada
Shinichiro Yamada
MSMitsuo Shimada
Mitsuo Shimada
YMYuji Morine
Yuji Morine
SISatoru Imura
Satoru Imura
TITetsuya Ikemoto
Tetsuya Ikemoto
MNMasaaki Nishi
Masaaki Nishi
Background: Frailty is an important consideration for older patients undergoing surgery. We aimed to investigate whether frailty could be a prognostic factor in patients with pancreatic ductal adenocarcinoma who underwent pancreatic resection. Methods: One hundred and twenty patients who underwent pancreatic resection for pancreatic ductal adenocarcinoma were enrolled. Frailty was defined as a clinical frailty scale score ≥4. Patients were divided into frailty (n = 29) and non-frailty (n=91) groups, and clinicopathological factors were compared between the two groups. Results: The frailty group showed an older age, lower serum albumin concentration, lower prognostic nutritional index, larger tumor diameter, and higher rate of lymph node metastasis than the non-frailty group (p < 0.05). Neutrophil–lymphocyte ratio and modified Glasgow prognostic score tended to be higher in the frailty group. Cancer-specific and disease-free survival rates were significantly poor in the frailty group (p < 0.05). With a multivariate analysis, frailty was an independent prognostic factor of cancer-specific survival. Conclusions: Frailty can predict the prognosis of patients with pancreatic ductal adenocarcinoma who undergo pancreatic resection.

14 January 2022 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
SCShuhai Chen
Shuhai Chen
MNMasaaki Nishi
Masaaki Nishi
YMYuji Morine
Yuji Morine
MSMitsuo Shimada
Mitsuo Shimada
TTTakuya Tokunaga
Takuya Tokunaga
YWYuma Wada
Yuma Wada
In recent times, researchers working on tumor metabolism have paid increasing attention to the tumor microenvironment. Emerging evidence has confirmed that epigenetic modifications of cancer‑associated fibroblasts (CAFs) alters the characteristics of glucose metabolism to achieve a symbiotic relationship with the cancer cells. Epigallocatechin‑3‑gallate (EGCG) exerts anti‑tumor effects via a variety of mechanisms, although the underlying mechanism that accounts for the effects of EGCG on glucose metabolic alterations of CAFs have yet to be elucidated. In the present study, through co‑culture with colorectal cancer (CRC) cells, human intestinal fibroblasts were transformed into CAFs, and exhibited enhanced aerobic glycolysis. Induced CAFs were able to enhance the proliferation, migration and invasion of CRC cells in vitro. EGCG treatment led to direct inhibition of the proliferation and migration of CRC cells; furthermore, EGCG treatment of CAFs suppressed their tumor‑promoting capabilities by inhibiting their glycolytic activity. Blocking the lactic acid efflux of CAFs with a monocarboxylate transporter 4 (MCT4) inhibitor or through silencing MCT4 could also suppress their tumor‑promoting capabilities, indicating that lactate fulfills an important role in the metabolic coupling that occurs between CAFs and cancer cells. Taken together, the results of the present study showed that EGCG targeting of the metabolism of tumor stromal cells provided a safe and effective strategy of anti‑cancer therapy.

16 February 2021 in Oncotarget
Verified
Journal Article
Open access
PDF file
KTKazunori Tokuda
Kazunori Tokuda
YMYuji Morine
Yuji Morine
KMKatsuki Miyazaki
Katsuki Miyazaki
SYShinichiro Yamada
Shinichiro Yamada
YSYu Saito
Yu Saito
MSMitsuo Shimada
Mitsuo Shimada
Https://doi.org/10.18632/oncotarget.27881 Kazunori Tokuda, Yuji Morine, Katsuki Miyazaki, Shinichiro Yamada, Yu Saito, Masaaki Nishi, Takuya Tokunaga, Tetsuya Ikemoto, Satoru Imura, Mitsuo Shimada

30 June 2022 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YWYuma Wada
Yuma Wada
MNMasaaki Nishi
Masaaki Nishi
KYKozo Yoshikawa
Kozo Yoshikawa
CTChie Takasu
Chie Takasu
TTTakuya Tokunaga
Takuya Tokunaga
MSMitsuo Shimada
Mitsuo Shimada

30 May 2018 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
MNMasaaki Nishi
Masaaki Nishi
KYKozo Yoshikawa
Kozo Yoshikawa
JHJun Higashijima
Jun Higashijima
TTTakuya Tokunaga
Takuya Tokunaga
HKHideya Kashihara
Hideya Kashihara
MSMitsuo Shimada
Mitsuo Shimada
Background/Aim: Indoleamine 2,3-dioxygenase (IDO) down-regulates T cell activation, attenuates regulatory T cell (Treg) activation and is related to immune tolerance. The aim of the study was to clarify the significance of IDO expression and analyze the relationships between the expression of IDO, TGF-β, and Foxp3 in gastric cancer (GC). Patients and Methods: A total of 60 patients who underwent curative gastrectomy for stage III gastric cancer were included in the study. The expression of IDO, TGF-β, and Foxp3 was examined by immunohistochemistry and the relationship of each expression level to several prognostic factors was examined using univariate and multivariate analyses. Results: IDO expression was not positively correlated with any of the factors examined. IDO expression was positively correlated with TGF-β expression (p<0.05), and TGF-β expression was positively correlated with FoxP3 expression (p<0.05). Overall survival (OS) rates were significantly poorer in the IDO-positive group compared to the IDO-negative group (3-year OS, 78.5% vs. 90%, respectively; p<0.05). Multivariate analysis confirmed IDO expression as independent prognostic factors in OS. Disease-free survival (DFS) was significantly poorer in the IDO-positive group compared to the IDO-negative group (3-year DFS, 59.3% vs. 69.3%, respectively; p<0.05). Conclusion: IDO is associated with poor prognosis and immuno-tolerance through attenuation of Treg activation in Stage III GC.